Development of New Targeted Nanotherapy Combined with Magneto-Fluorescent Nanoparticles against Colorectal Cancer
Marcelo, Gonçalo A. (Universidade Nova de Lisboa. Departamento de Química)
Montpeyó Garcia-Moreno, David (Universitat Autònoma de Barcelona. Institut de Biotecnologia i de Biomedicina "Vicent Villar Palasí")
Galhano, Joana (Universidade Nova de Lisboa. Departamento de Química)
Martínez-Máñez, Ramón (Universitat Politècnica de València. Instituto Interuniversitario de Investigación de Reconocimiento Molecular y Desarrollo Tecnológico)
Capelo-Martínez, José Luis (Universidade Nova de Lisboa. Departamento de Química)
Lorenzo Rivera, Julia (Universitat Autònoma de Barcelona. Departament de Bioquímica i de Biologia Molecular)
Lodeiro, Carlos (Universidade Nova de Lisboa. Departamento de Química)
Oliveira, Elisabete (Universidade Nova de Lisboa. Departamento de Química)

Fecha:	2023
Resumen:	The need for non-invasive therapies capable of conserving drug efficiency and stability while having specific targetability against colorectal cancer (CRC), has made nanoparticles preferable vehicles and principal building blocks for the development of complex and multi-action anti-tumoral approaches. For that purpose, we herein report the production of a combinatory anti-tumoral nanotherapy using the production of a new targeting towards CRC lines. To do so, Magneto-fluorescent NANO3 nanoparticles were used as nanocarriers for a combination of the drugs doxorubicin (DOX) and ofloxacin (OFLO). NANO3 nanoparticles' surface was modified with two different targeting agents, a newly synthesized (anti-CA IX acetazolamide derivative (AZM-SH)) and a commercially available (anti-epidermal growth factor receptor (EGFR), Cetuximab). The cytotoxicity revealed that only DOX-containing nanosystems showed significant and even competitive cytotoxicity when compared to that of free DOX. Interestingly, surface modification with AZM-SH promoted an increased cellular uptake in the HCT116 cell line, surpassing even those functionalized with Cetuximab. The results show that the new target has high potential to be used as a nanotherapy agent for CRC cells, surpassing commercial targets. As a proof-of-concept, an oral administration form of NANO3 systems was successfully combined with Eudragit ® enteric coating and studied under extreme conditions.
Ayudas:	Agencia Estatal de Investigación PID2021-127983OB-C22 Agencia Estatal de Investigación PID2021-126304OB-C41
Nota:	Altres ajuts: Generalitat Valenciana (CIPROM/2021/007)
Derechos:	Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, la comunicació pública de l'obra i la creació d'obres derivades, fins i tot amb finalitats comercials, sempre i quan es reconegui l'autoria de l'obra original.
Lengua:	Anglès
Documento:	Article ; recerca ; Versió publicada
Materia:	Target nanocarriers ; Oral formulations ; Colorectal cancer ; Target drug delivery ; Targeted anticancer therapy
Publicado en:	International journal of molecular sciences, Vol. 24, Issue 7 (April 2023) , art. 6612, ISSN 1422-0067

DOI: 10.3390/ijms24076612
PMID: 37047582

23 p, 4.6 MB

El registro aparece en las colecciones:
Documentos de investigación > Documentos de los grupos de investigación de la UAB > Centros y grupos de investigación (producción científica) > Ciencias de la salud y biociencias > Instituto de Biotecnología y de Biomedicina (IBB)
Artículos > Artículos de investigación
Artículos > Artículos publicados